219 related articles for article (PubMed ID: 23835704)
1. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.
Weston BW; Hayden MA; Roberts KG; Bowyer S; Hsu J; Fedoriw G; Rao KW; Mullighan CG
J Clin Oncol; 2013 Sep; 31(25):e413-6. PubMed ID: 23835704
[No Abstract] [Full Text] [Related]
2. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.
Lengline E; Beldjord K; Dombret H; Soulier J; Boissel N; Clappier E
Haematologica; 2013 Nov; 98(11):e146-8. PubMed ID: 24186319
[No Abstract] [Full Text] [Related]
3. TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation.
Kobayashi K; Miyagawa N; Mitsui K; Matsuoka M; Kojima Y; Takahashi H; Ootsubo K; Nagai J; Ueno H; Ishibashi T; Sultana S; Okada Y; Akimoto S; Okita H; Matsumoto K; Goto H; Kiyokawa N; Ohara A
Pediatr Blood Cancer; 2015 Jun; 62(6):1058-60. PubMed ID: 25400122
[TBL] [Abstract][Full Text] [Related]
4. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.
Leoni V; Biondi A
Haematologica; 2015 Mar; 100(3):295-9. PubMed ID: 25740105
[No Abstract] [Full Text] [Related]
6. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
7. [Outcome of autologous hematopoietic stem cell transplantation in combination with imatinib for 16 cases of Philadelphia chromosome positive acute lymphoblastic leukemia].
Liu X; Jiang E; Huang Y; Yang D; Pang A; Wei J; Ma Q; Zhang R; Qiu L; Feng S; Han M
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):250-2. PubMed ID: 24666497
[No Abstract] [Full Text] [Related]
8. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.
Schwab C; Ryan SL; Chilton L; Elliott A; Murray J; Richardson S; Wragg C; Moppett J; Cummins M; Tunstall O; Parker CA; Saha V; Goulden N; Vora A; Moorman AV; Harrison CJ
Blood; 2016 May; 127(18):2214-8. PubMed ID: 26872634
[TBL] [Abstract][Full Text] [Related]
9. Long-term imatinib maintenance therapy for adult Philadelphia positive acute lymphoblastic leukemia.
Guillet S; Hirsch P; Marzac C; Mohty M; Marie JP; Legrand O
Leuk Lymphoma; 2014 Nov; 55(11):2646-8. PubMed ID: 24491028
[No Abstract] [Full Text] [Related]
10. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
11. Time to tune the treatment of Ph+ ALL.
Yanada M
Blood; 2015 Jun; 125(24):3674-5. PubMed ID: 26069331
[TBL] [Abstract][Full Text] [Related]
12. Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.
Sonmez M; Cobanoglu U; Ovali E; Omay SB
J Clin Pharm Ther; 2008 Jun; 33(3):329-30. PubMed ID: 18452422
[No Abstract] [Full Text] [Related]
13. [Current chemotherapy of adult acute lymphoblastic leukemia].
Usui N
Rinsho Ketsueki; 2010 Oct; 51(10):1549-57. PubMed ID: 20962489
[No Abstract] [Full Text] [Related]
14. Sequential tyrosine kinase inhibitor therapy: sustained disease remission in Philadelphia-positive erythroleukaemia.
Craig J; Walker K; Sales M; Cunningham J; Gelly K; Pippard MJ; Tauro S
Br J Haematol; 2008 Aug; 142(4):674-5. PubMed ID: 18485048
[No Abstract] [Full Text] [Related]
15. [Hypoprotidemia may explain imatinib intoxication in a patient with Philadelphia-positive acute lymphoblastic leukemia].
Gaïes E; Trabelsi S; Sahnoun R; Salouage I; Jebabli N; Charfi R; Lakhal M; Hdiji S; Klouz A
Therapie; 2013; 68(2):125-7. PubMed ID: 23773356
[No Abstract] [Full Text] [Related]
16. Advances in the management of Ph-positive ALL.
Hoelzer D
Clin Adv Hematol Oncol; 2006 Nov; 4(11):804-5. PubMed ID: 17143248
[No Abstract] [Full Text] [Related]
17. Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.
Zhang G; Zhang Y; Wu J; Chen Y; Ma Z
Am J Case Rep; 2017 Nov; 18():1204-1208. PubMed ID: 29133777
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.
Levitzki A
Annu Rev Pharmacol Toxicol; 2013; 53():161-85. PubMed ID: 23043437
[TBL] [Abstract][Full Text] [Related]
19. Effective treatment with imatinib for acute B-lymphoblastic leukaemia with EBF1-PDGFRB fusion.
Horiuchi M; Yoshida M; Yamasaki K; Sakagami R; Aoyama T; Tatsumi N; Tsutsumi M; Nakaya Y; Fuseya H; Yoshimura T; Hayashi Y; Nakao T; Yamane T
Ann Hematol; 2021 May; 100(5):1329-1331. PubMed ID: 33150465
[No Abstract] [Full Text] [Related]
20. [Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].
Hochhaus A
Dtsch Med Wochenschr; 2002 Mar; 127(9):451-6. PubMed ID: 11870560
[No Abstract] [Full Text] [Related]
[Next] [New Search]
